![Vertex Pharmaceuticals Incorporated Website](https://cdn.finchat.io/36235.png)
Vertex Pharmaceuticals Incorporated
NasdaqGS-VRTX
Company Overview
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Name
Vertex Pharmaceuticals Incorporated
CEO
Dr. Reshma Kewalramani FASN, M.D.
Website
www.vrtx.com
Sector
Biotechnology
Year Founded
1989
Profile
Market Cap
$120.94B
EV
$111.68B
Shares Out
258.1M
Revenue
$10.34B
Employees
5,400
Margins
Gross
53.65%
EBITDA
42.51%
Operating
40.61%
Pre-Tax
2.08%
Net
-4.74%
FCF
-11.42%
Returns (5Yr Avg)
ROA
20.35%
ROTA
28.61%
ROE
27.52%
ROCE
30.42%
ROIC
58.78%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
$509.82
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
$5,795.5M
Net Debt
-$9,255.2M
Debt/Equity
0.06
EBIT/Interest
100.43
Growth (CAGR)
Rev 3Yr
15.65%
Rev 5Yr
24.51%
Rev 10Yr
28.69%
Dil EPS 3Yr
-36.91%
Dil EPS 5Yr
-25.89%
Dil EPS 10Yr
-0.66%
Rev Fwd 2Yr
9.31%
EBITDA Fwd 2Yr
12.4%
EPS Fwd 2Yr
10.26%
EPS LT Growth Est
35%
Dividends
Yield
—
Payout
—
DPS
—
DPS Growth 3Yr
—
DPS Growth 5Yr
—
DPS Growth 10Yr
—
DPS Growth Fwd 2Yr
—